HealthQuill Major Depressive Disorder
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at least two oral antidepressants for treating major depressive disorder.
Uncategorized

J&J’s nasal spray to treat major depressive disorder gets FDA nod

The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.

Read More
Anxiety disorders during childhood can impact employment, difficulties in the workplace, and adult depression, a study by the University of Oxford found.
Health Medical Research

Major headway in depression study: 293 new genetic variants found

HQ Team January 20, 2025: Research has unveiled 293 new gene variants linked to major depressive disorder (MDD), significantly enhancing our understanding of.

Read More